BioCentury | Feb 28, 2018
Distillery Therapeutics

Autoimmune disease

...treat Alzheimer’s disease and preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope and Blanchette Rockefeller Neurosciences Institute...
BioCentury | Oct 17, 2017
Distillery Techniques

Chemistry

...Alzheimer’s disease and in preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope and Blanchette Rockefeller Neurosciences Institute...
BioCentury | Apr 20, 2015
Clinical News

Bryostatin-1 regulatory update

...disease (AD) (see BioCentury, March 23). Neurotrope has a license to bryostatin-1 from the institute. Blanchette Rockefeller Neurosciences Institute...
BioCentury | May 6, 2013
Emerging Company Profile

Neurotrope: Saving synapses

...PKC. He continued to study PKC's role in memory pathology as scientific director of the Blanchette Rockefeller Neurosciences Institute...
...and seek FDA approval for the diagnostic after screening 300 patients. Companies and Institutions Mentioned Blanchette Rockefeller Neurosciences Institute...
...status: Phase II Founded: 2012 by John Abeles, Daniel Alkon and Jim New University collaborators: Blanchette Rockefeller Neurosciences Institute...
BioCentury | Sep 12, 2011
Company News

AssureRx management update

AssureRx Health Inc. , Mason, Ontario Business: Pharmacogenetics Hired: C. Anthony Altar as SVP and chief scientific officer, formerly director of the Alzheimer's Diagnostic Laboratory at the Blanchette Rockefeller Neuroscience Institute WIR Staff Diagnostic...
BioCentury | Feb 17, 2011
Distillery Therapeutics

Indication: Neurology

...Next steps include in vitro optimization of new chemical entities for potential PKCE agonist activity. Blanchette Rockefeller Neurosciences Institute...
...AD. SciBX 4(7); doi:10.1038/scibx.2011.198 Published online Feb. 17, 2011 Patented; available for licensing from the Blanchette Rockefeller Neurosciences Institute...
...J. et al. J. Neurosci.; published online Jan. 12, 2011; doi:10.1523/JNEUROSCI.5209-10.2011 Contact: Daniel L. Alkon, Blanchette Rockefeller Neurosciences Institute...
BioCentury | Jun 8, 2009
Company News

Inverness, Blanchette Rockefeller Neurosciences Institute deal

...uses the technology. Further terms were not disclosed. Inverness Medical Innovations Inc. (NYSE:IMA), Waltham, Mass. Blanchette Rockefeller Neurosciences Institute...
BioCentury | Aug 19, 2006
Clinical News

Researchers publish skin test for AD

...Researchers from Blanchette Rockefeller Neurosciences Institute published in the Proceedings of the National Academy of Sciences that an assay...
BioCentury | Jul 26, 2004
Company News

Blanchette Rockefeller Neurosciences Institute other research news

...compared to controls. Data were published in the Proceedings of the National Academy of Sciences. Blanchette Rockefeller Neurosciences Institute...
BioCentury | Jul 26, 2004
Tools & Techniques

Flipping the idea

Initial attempts to develop bryostatin 1 have been disappointing for cancer researchers because of myalgia, a dose-limiting toxicity. But the protein kinase C modulator may have applications in other indications, in particular Alzheimer's disease (AD),...
Items per page:
1 - 10 of 10
BioCentury | Feb 28, 2018
Distillery Therapeutics

Autoimmune disease

...treat Alzheimer’s disease and preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope and Blanchette Rockefeller Neurosciences Institute...
BioCentury | Oct 17, 2017
Distillery Techniques

Chemistry

...Alzheimer’s disease and in preclinical testing to treat Niemann-Pick disease type C (NPC). Neurotrope and Blanchette Rockefeller Neurosciences Institute...
BioCentury | Apr 20, 2015
Clinical News

Bryostatin-1 regulatory update

...disease (AD) (see BioCentury, March 23). Neurotrope has a license to bryostatin-1 from the institute. Blanchette Rockefeller Neurosciences Institute...
BioCentury | May 6, 2013
Emerging Company Profile

Neurotrope: Saving synapses

...PKC. He continued to study PKC's role in memory pathology as scientific director of the Blanchette Rockefeller Neurosciences Institute...
...and seek FDA approval for the diagnostic after screening 300 patients. Companies and Institutions Mentioned Blanchette Rockefeller Neurosciences Institute...
...status: Phase II Founded: 2012 by John Abeles, Daniel Alkon and Jim New University collaborators: Blanchette Rockefeller Neurosciences Institute...
BioCentury | Sep 12, 2011
Company News

AssureRx management update

AssureRx Health Inc. , Mason, Ontario Business: Pharmacogenetics Hired: C. Anthony Altar as SVP and chief scientific officer, formerly director of the Alzheimer's Diagnostic Laboratory at the Blanchette Rockefeller Neuroscience Institute WIR Staff Diagnostic...
BioCentury | Feb 17, 2011
Distillery Therapeutics

Indication: Neurology

...Next steps include in vitro optimization of new chemical entities for potential PKCE agonist activity. Blanchette Rockefeller Neurosciences Institute...
...AD. SciBX 4(7); doi:10.1038/scibx.2011.198 Published online Feb. 17, 2011 Patented; available for licensing from the Blanchette Rockefeller Neurosciences Institute...
...J. et al. J. Neurosci.; published online Jan. 12, 2011; doi:10.1523/JNEUROSCI.5209-10.2011 Contact: Daniel L. Alkon, Blanchette Rockefeller Neurosciences Institute...
BioCentury | Jun 8, 2009
Company News

Inverness, Blanchette Rockefeller Neurosciences Institute deal

...uses the technology. Further terms were not disclosed. Inverness Medical Innovations Inc. (NYSE:IMA), Waltham, Mass. Blanchette Rockefeller Neurosciences Institute...
BioCentury | Aug 19, 2006
Clinical News

Researchers publish skin test for AD

...Researchers from Blanchette Rockefeller Neurosciences Institute published in the Proceedings of the National Academy of Sciences that an assay...
BioCentury | Jul 26, 2004
Company News

Blanchette Rockefeller Neurosciences Institute other research news

...compared to controls. Data were published in the Proceedings of the National Academy of Sciences. Blanchette Rockefeller Neurosciences Institute...
BioCentury | Jul 26, 2004
Tools & Techniques

Flipping the idea

Initial attempts to develop bryostatin 1 have been disappointing for cancer researchers because of myalgia, a dose-limiting toxicity. But the protein kinase C modulator may have applications in other indications, in particular Alzheimer's disease (AD),...
Items per page:
1 - 10 of 10